Apremilast for treating active psoriatic arthritis

3 Evidence

The appraisal committee (section 6) considered evidence submitted by Celgene and a review of this submission by the evidence review group. This appraisal was a rapid review of the published NICE technology appraisal guidance on apremilast for treating psoriatic arthritis (TA372). It focused on cost‑effectiveness analyses using a patient access scheme agreement, which provides apremilast at a reduced cost. The discount is commercial in confidence. See the committee papers for full details of the rapid review evidence, and the history for full details of the evidence used for NICE's original technology appraisal guidance on apremilast for treating psoriatic arthritis. See section 4.24 onwards for the rapid review consideration.